Literature DB >> 32076845

Imagery Rescripting for Anxiety Disorders and Obsessive-Compulsive Disorder: Recent Advances and Future Directions.

Laura P Strachan1, Matthew P Hyett1, Peter M McEvoy2,3.   

Abstract

PURPOSE OF REVIEW: This review describes imagery rescripting (ImRs) and its clinical application to anxiety disorders and obsessive-compulsive disorder (OCD). Variations in ImRs delivery, clinical evidence, and theories of potential mechanisms of change are also reviewed. Finally, we propose a future research agenda. RECENT
FINDINGS: There is some evidence that ImRs affects memory processes and schemas. ImRs is associated with reductions in cognitive-affective, physiological and behavioural symptoms of social anxiety disorder and reductions in OCD-related distress and OCD symptoms. ImRs for other anxiety disorders has not been evaluated. While ImRs appears to be an effective intervention for social anxiety disorder and OCD, more research is needed to (a) systematically compare ImRs to established interventions, (b) evaluate ImRs for other anxiety disorders, (c) test theorized mechanisms of change, and (d) evaluate the impact of moderating factors and treatment variations on therapeutic outcomes.

Entities:  

Keywords:  Anxiety disorders; Imagery rescripting; Obsessive-compulsive disorder; Review; Social anxiety disorder

Year:  2020        PMID: 32076845     DOI: 10.1007/s11920-020-1139-4

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  2 in total

Review 1.  Delivering Imagery Rescripting via Telehealth: Clinical Concerns, Benefits, and Recommendations.

Authors:  Georgie Paulik; Gayle Maloney; Arnoud Arntz; Nathan Bachrach; Annemieke Koppeschaar; Peter McEvoy
Journal:  Curr Psychiatry Rep       Date:  2021-03-16       Impact factor: 5.285

2.  Mental imagery in adolescent PTSD patients after child abuse: a comparison with matched healthy controls.

Authors:  Regina Steil; Anne Fischer; Jana Gutermann; Rita Rosner
Journal:  BMC Psychiatry       Date:  2022-01-27       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.